Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $64.4286.

Several brokerages have recently weighed in on DNTH. Truist Financial increased their price target on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush reiterated an “outperform” rating and issued a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday, December 22nd. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $39.12 on Tuesday. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $45.46. The firm has a market cap of $1.68 billion, a PE ratio of -11.24 and a beta of 1.55. The firm’s fifty day moving average is $40.79 and its 200-day moving average is $32.33.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Sell-side analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $152,560. The trade was a 96.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 216,538 shares of company stock worth $8,283,175. 16.56% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $765,000. JPMorgan Chase & Co. lifted its position in shares of Dianthus Therapeutics by 626.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after acquiring an additional 58,746 shares during the period. TCG Crossover Management LLC boosted its stake in Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares in the last quarter. Vivo Capital LLC bought a new position in Dianthus Therapeutics during the third quarter worth $13,930,000. Finally, Polar Capital Holdings Plc acquired a new stake in Dianthus Therapeutics in the third quarter worth $29,434,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.